KRAS and Miyoshi myopathy: Indeed, the mTORC1 signature was significantly enriched in MM samples harboring mutations in either KRAS, NRAS or FGFR3 (P = 0.011) (Fig. 6d), validating a link between oncogenic RAS signaling and mTORC1 activity in primary MM cases.